VRDN Earnings & Financial Statements
Viridian Therapeutics, Inc.
$18.34
+$0.06(+0.33%)
46
Overall
60
Value
45
Tech
34
Quality
Market Cap
$2.07B
Volume
2.44M
52W Range
$13.18 - $34.29
Target Price
$36.88
VRDN earnings and financial statements: Viridian Therapeutics, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
VRDN Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $70.85M | $302.0K | $314.0K | $1.77M | $2.96M |
| Operating income | -$363.39M | -$299.04M | -$254.45M | -$134.30M | -$79.73M |
| EBITDA | -$337.19M | -$267.21M | -$235.05M | -$128.91M | -$79.29M |
| Net income | -$342.60M | -$269.95M | -$237.73M | -$129.87M | -$79.41M |
| EPS (diluted) | - | $-3.07 | $-5.31 | $-4.05 | $-6.66 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $899.42M | $742.40M | $490.42M | $435.09M | $203.71M |
| Total liabilities | $177.25M | $70.76M | $48.40M | $40.03M | $15.99M |
| Shareholders’ equity | $722.17M | $671.64M | $442.02M | $395.06M | $187.72M |
| Cash and equivalents | - | - | $477.40M | $424.60M | $197.00M |
| Long-term debt | $84.18M | $20.58M | $20.20M | $4.64M | - |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$276.39M | -$232.32M | -$184.17M | -$93.84M | -$54.58M |
| Capital expenditure | -$495.0K | -$511.0K | -$898.0K | -$797.0K | -$338.0K |
| Free cash flow | -$276.89M | -$232.83M | -$185.07M | -$94.64M | -$54.92M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | VRDN | $18.34 | +0.3% | 2.44M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Viridian Therapeutics, Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW